Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.
Type:
Application
Filed:
October 7, 2019
Publication date:
September 3, 2020
Applicant:
University of Washington through its Center for Commercialization
Inventors:
Michael J. Gale, JR., Gretja Schnell, Yueh-Ming Loo
Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
Type:
Grant
Filed:
July 3, 2019
Date of Patent:
September 1, 2020
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jesse Salk, Lawrence A. Loeb, Michael Schmitt
Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
Type:
Grant
Filed:
July 17, 2019
Date of Patent:
August 25, 2020
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jesse Salk, Lawrence A. Loeb, Michael Schmitt
Abstract: The present invention provides, among other aspects, stabilized chromophoric nanoparticles. In certain embodiments, the chromophoric nanoparticles provided herein are rationally functionalized with a pre-determined number of functional groups. In certain embodiments, the stable chromophoric nanoparticles provided herein are modified with a low density of functional groups. In yet other embodiments, the chromophoric nanoparticles provided herein are conjugated to one or more molecules. Also provided herein are methods for making rationally functionalized chromophoric nanoparticles.
Type:
Grant
Filed:
May 27, 2016
Date of Patent:
August 11, 2020
Assignee:
University of Washington through its Center for Commercialization
Inventors:
Daniel T. Chiu, Changfeng Wu, Xuanjun Zhang, Jiangbo Yu, Fangmao Ye
Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
Type:
Grant
Filed:
May 13, 2019
Date of Patent:
July 14, 2020
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jesse Salk, Lawrence A. Loeb, Michael Schmitt
Abstract: Contiguity information is important to achieving high-quality de novo assembly of mammalian genomes and the haplotype-resolved resequencing of human genomes. The methods described herein pursue cost-effective, massively parallel capture of contiguity information at different scales.
Type:
Application
Filed:
October 28, 2019
Publication date:
July 9, 2020
Applicant:
University of Washington Through Its Center for Commercialization
Inventors:
Jay Ashok Shendure, Jerrod Joseph Schwartz, Andrew Colin Adey, Cho li Lee, Joseph Brian Hiatt, Jacob Otto Kitzman, Akash Kumar
Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
Type:
Grant
Filed:
May 13, 2019
Date of Patent:
June 23, 2020
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jesse Salk, Lawrence A. Loeb, Michael Schmitt
Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
Type:
Grant
Filed:
May 13, 2019
Date of Patent:
June 23, 2020
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jesse Salk, Lawrence A. Loeb, Michael Schmitt
Abstract: Methods, devices, and systems for performing digital assays are provided. In certain aspects, the methods, devices, and systems can be used for the amplification and detection of nucleic acids. In certain aspects, the methods, devices, and systems can be used for the recognition, detection, and sizing of droplets in a volume. Also provided are compositions and kits suitable for use with the methods and devices of the present disclosure.
Type:
Grant
Filed:
April 8, 2015
Date of Patent:
April 14, 2020
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Daniel T. Chiu, Jason E. Kreutz, Gloria S. Yen, Bryant S. Fujimoto
Abstract: The present invention provides recombinant adenoviral compositions and methods for their use in treating disorders associated with epithelial tissues.
Type:
Grant
Filed:
November 30, 2018
Date of Patent:
April 7, 2020
Assignee:
University of Washington Through Its Center For Commercialization
Abstract: The present disclosure generally relates to the methods and compositions to efficiently analyze polymer characteristics using nanopore-based assays. Specifically disclosed is a method for generating reference signals for polymer analysis in a nanopore system, wherein the nanopore system has a multi-subunit output signal resolution. The method comprises translocating a reference sequence through a nanopore to generate a plurality of reference output signals, wherein each possible multi-subunit sequence that can determine an output signal appears only once in the reference sequence. The output signals are compiled into a reference map for nanopore analysis of an analyte polymer. Also provided are methods and compositions for calibrating the nanopore system for optimized polymer analysis.
Type:
Grant
Filed:
April 19, 2013
Date of Patent:
April 7, 2020
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jens Gundlach, Ian M. Derrington, Andrew Laszlo, Elizabeth Manrao
Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
Type:
Grant
Filed:
May 13, 2019
Date of Patent:
March 31, 2020
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jesse Salk, Lawrence A. Loeb, Michael Schmitt
Abstract: Methods for diagnosing a pathologic tissue membrane, as well as a focused ultrasound apparatus and methods of treatment are disclosed to perform ureterocele puncture noninvasively using focused ultrasound-generated cavitation or boiling bubbles to controllably erode a hole through the tissue. An example ultrasound apparatus may include (a) a therapy transducer having a treatment surface, wherein the therapy transducer comprises a plurality of electrically isolated sections, (b) at least one concave acoustic lens defining a therapy aperture in the treatment surface of the therapy transducer, (c) an imaging aperture defined by either the treatment surface of the therapy transducer or by the at least one concave acoustic lens and (d) an ultrasound imaging probe axially aligned with a central axis of the therapy aperture.
Type:
Application
Filed:
June 20, 2019
Publication date:
March 12, 2020
Applicants:
University of Washington through its Center for Commercialization, The Trustees of Columbia University in the City of New York
Inventors:
Adam Maxwell, Ryan Hsi, Thomas Lendvay, Pasquale Casale, Michael Bailey
Abstract: In a first aspect, the present invention provides methods for creating video signals including (a) receiving an input video signal including an input red component, an input green component, and an input blue component; (b) determining (i) that a magnitude of the input red component is greater than a magnitude of the input green component and (ii) a differential between the magnitude of the input red component and the magnitude of the input green component; and (c) sending an output video signal including an output red component, an output green component, and an output blue component, where at least one of the following is true: (i) the output red component is decreased by a fractional amount relative to the input red component based on the differential; and/or (ii) the output green component is increased by a fractional amount relative to the input green component based on the differential, and the output blue component is increased by a fractional amount relative to the input blue component based on the di
Type:
Grant
Filed:
March 29, 2018
Date of Patent:
March 10, 2020
Assignee:
University of Washington Through Its Center for Commercialization
Inventors:
Jay Neitz, James Kuchenbecker, Maureen Neitz
Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
Type:
Grant
Filed:
August 31, 2018
Date of Patent:
February 25, 2020
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jesse Salk, Lawrence A. Loeb, Michael Schmitt
Abstract: Apparatus and method for photo-chemical oxidation are disclosed herein. In one embodiment, a method for regenerating a dialysis fluid includes: flowing the dialysis fluid between an anode and a cathode of a dialysis system, where the anode comprises a plurality of nanostructures; illuminating the anode with a source of light; flowing oxygen through the cathode toward the dialysis fluid; and converting urea in the dialysis fluid into CO2, N2 and H2O thereby regenerating the dialysis fluid.
Type:
Application
Filed:
August 8, 2019
Publication date:
February 20, 2020
Applicant:
University of Washington Through its Center for Commercialization
Abstract: Apparatus and method for photo-chemical oxidation are disclosed herein. In one embodiment, a dialysis fluid regeneration system includes: a nanostructured anode; a source of light configured to illuminate the anode; and a cathode that is oxygen permeable.
Type:
Application
Filed:
August 8, 2019
Publication date:
February 20, 2020
Applicant:
University of Washington Through its Center for Commercialization
Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
Type:
Grant
Filed:
January 11, 2019
Date of Patent:
February 18, 2020
Assignee:
University of Washington Through Its Center for Commercialization
Abstract: Provided herein are compositions and methods for identifying or quantitating one or more analytes in sample. The composition can comprise an affinity molecule reversibly conjugated to a label moiety via a double-stranded nucleic acid linker or via an adaptor molecule. The affinity molecule and the label moiety can be linked to different strands of the double-stranded nucleic acid linker. Compositions can be used in any biological assays for detection, identification and/or quantification of target molecules or analytes, including multiplex staining for molecular profiling of individual cells or cellular populations. For example, the compositions can be adapted for use in immunofluorescence, fluorescence in situ hybridization, immunohistochemistry, western blot, and the like.
Type:
Grant
Filed:
June 28, 2018
Date of Patent:
May 12, 2020
Assignee:
University of Washington through its Center for Commercialization